Long-term effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension: results from the PROLOGUE study.

Ziliang Ye,Qiang Su,Lang Li,Haili Lu,Hui Li

doi:10.18632/oncotarget.22959

Abstract

BackgroundThe effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension are unclear. Therefore, we evaluated the long-term effects of sitagliptin in those patients.MethodsIn the PROLOGUE study, 365 patients were diagnosed as type 2 diabetes mellitus and hypertension, and 189 patients in the sitagliptin group, 176 patients in the conventional group. Fasting blood glucose (FBG), HbA1c, systolic pressure (SP), diastolic pressure (DP), serum urea nitrogen (BUN) and serum creatinine (SCR) were measured at the beginning of the study and after 12 and 24 months of treatment.ResultsFBS and HbA1c levels were not significantly decreased after treatment [12 months: OR: -3.1, 95% CI (-11.3, 5.0); OR: 0.1, 95% CI (0.0, 0.3); 24 months: OR: -0.1, 95% CI (-9.1, 8.8); OR: 0.1, 95% CI (0.0, 0.3), respectively]. BP and DP levels were not significantly decreased after treatment (12 months: OR: 0.9, 95% CI (-2.8, 4.6); OR: 0.6, 95% CI (-2.0, 3.2); 24 months: OR: -0.5, 95% CI (-4.2, 3.1); OR: -1.6, 95% CI (-41, 0.9), respectively]. Furthermore, BUN and SCR levels were not significantly decreased after treatment (12 months: OR: 0.0, 95%CI (-1.2, 1.2); OR: 0.0, 95% CI (-0.1, 0.0); 24 months: OR: 0.4, 95% CI (-1.0, 1.8); OR: -80.8, 95% CI (-201.3, 39.8), respectively]. After adjusting for confounding factors, our results did not change.ConclusionsIn our study, there was no evidence that treatment with sitagliptin can improve FBS, BP, DP, BUN or SCR in patients with type 2 diabetes mellitus and hypertension.Trial RegistrationUniversity Hospital Medical Information Network Clinical Trials Registry UMIN000004490.

Highlights

With the development of the social economy, all kinds of pressure, the change in lifestyle and the aging population, the incidence of diabetes is increasing year by year
In our study, there was no evidence that treatment with sitagliptin can improve FBS, BP, diastolic pressure (DP), BUN or serum creatinine (SCR) in patients with type 2 diabetes mellitus and hypertension
The major finding of our study is that there was no evidence that treatment with sitagliptin can improve fasting glucose, HbA1c, systolic pressure or diastolic pressure in type 2 diabetes patients complicated with hypertension during a 2-year study period

Summary

Introduction

With the development of the social economy, all kinds of pressure, the change in lifestyle and the aging population, the incidence of diabetes is increasing year by year. Type 2 diabetes can cause disorders of glucose, lipid and protein metabolism, which can result in complications of the heart and peripheral vascular system (such as coronary heart disease and hypertension), endocrine and metabolic system (such as ketoacidosis and lactic acidosis), and others [5, 6]. Type 2 diabetes mellitus complicated with hypertension is a common clinical disease [7, 8]. Studies have shown that for patients with type 2 diabetes and hypertension, the control of blood glucose and blood pressure is more difficult than that of single disease [8, 9]. The effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension are unclear. We evaluated the long-term effects of sitagliptin in those patients

Methods

Results

Discussion

Conclusion